Try our Advanced Search for more refined results

In re Akorn, Inc. Securities Litigation

  1. June 05, 2018

    Class Counsel To Collect Over $6M In Akorn Accounting Row

    An Illinois federal judge on Tuesday awarded Pomerantz LLP and Glancy Prongay & Murray LLP more than $6 million in attorneys' fees in a class action brought by Akorn Pharmaceuticals investors who claimed that Akorn Inc. failed to properly track its finances, leading the company to misstate its revenue.

  2. November 28, 2017

    Akorn, Investors Get Initial OK For $24M Accounting Deal

    An Illinois federal judge granted preliminary approval Tuesday for Akorn Pharmaceuticals to pay $24 million to end class allegations the company inflated revenue figures based on faulty accounting practices.

  3. November 21, 2017

    Akorn Reaches $24M Deal To End Investors' Accounting Suit

    Specialty drugmaker Akorn Inc. has reached a $24 million deal to settle a proposed investor class action alleging that the company's failure to fix widespread accounting problems and weak internal controls led it to report inflated revenue figures to the market, according to papers filed in Illinois federal court on Monday.

  4. March 06, 2017

    Akorn Must Face Claims In VersaPharm Integration Suit

    A group of Akorn Inc. shareholders got the go-ahead Monday in Illinois federal court to proceed with their claims that officials of the drugmaker inflated share prices by withholding damaging financial information.

  5. March 05, 2015

    Akorn Hid Delays Integrating VersaPharm, Shareholder Says

    Akorn Inc. failed to disclose it was lagging in integrating VersaPharm Inc. and another newly acquired subsidiary into its accounting system, artificially inflating the market price of its securities, an Akorn shareholder alleged in a securities lawsuit filed in Illinois federal court Wednesday.